26 completed, 6 terminated, 2 active not recruiting, 2 unknown. 10 Phase 4, 5 Phase 3, 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 6, Terminated 3, Unknown 1 |
| Phase 3 | 5 | Completed 4, Active not recruiting 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Astellas Pharma Europe Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE) Zolbetuximab Exposure, Platinum-based Chemotherapy Exposure, 1L Treatment Not Containing Zolbetuximab Exposure - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Not yet recruiting | Astellas Pharma Europe Ltd. | 1000 | 2026-10-31 | 2026-10-05 | |
| A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice Fezolinetant - Hot Flashes | Recruiting | Astellas Pharma Europe Ltd. | 238 | 2025-10-23 | 2026-05-22 | |
| A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause Fezolinetant - Hot Flashes | Completed | Astellas Pharma Europe Ltd. | 105 | 2024-10-29 | 2026-08-10 | |
| A Survey About Trade-offs When Choosing Menopause Treatments No Intervention - Moderate to Severe Vasomotor Symptoms | Completed | Astellas Pharma Europe Ltd. | 1465 | 2022-08-17 | 2024-10-26 | |
| Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. Enzalutamide capsule - Prostate Cancer | Phase 2 | Active not recruiting | CHU de Quebec-Universite Laval | 50 | 2022-03-22 | 2025-12-23 |
| A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) Register Non-interventional - Chronic Kidney Disease | Completed | Astellas Pharma Europe Ltd. | 45637 | 2021-11-30 | 2024-10-31 | |
| A Survey About Hot Flashes in Women Going Through the Menopause No Intervention - Menopause, Vasomotor Symptoms | Completed | Astellas Pharma Europe Ltd. | 2176 | 2021-11-04 | 2024-10-26 | |
| Enzalutamide Treatment in COVID-19 Enzalutamide Pill - COVID-19, Corona Virus Infection | Phase 2 | Terminated | Andreas Josefsson | 42 | 2020-07-15 | 2022-06-02 |
| Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis Non-interventional - Chronic Kidney Disease (CKD) | Completed | Astellas Pharma Europe Ltd. | 2773 | 2019-05-22 | 2024-10-31 | |
| A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death No intervention - Prostate Cancer | Completed | Astellas Pharma Europe Ltd. | 6908 | 2018-09-13 | 2025-01-13 | |
| A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients tacrolimus - Kidney Transplantation, Liver Transplantation | Phase 4 | Completed | Astellas Pharma Europe Ltd. | 80 | 2018-03-20 | 2018-10-15 |
| Phase III Radium 223 mCRPC-PEACE III Ra223, Enzalutamide - Prostate Cancer | Phase 3 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 446 | 2015-10-01 | 2025-09-19 |
| European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) enzalutamide - Metastatic Castration Resistant Prostate Cancer | Completed | Astellas Pharma Europe Ltd. | 1763 | 2015-09-08 | 2024-10-21 | |
| Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) fidaxomicin - Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI) | Phase 4 | Completed | Astellas Pharma Europe Ltd. | 25 | 2015-08-13 | 2024-10-31 |
| Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients Tacrolimus - Kidney Transplantation | Completed | Astellas Pharma Europe Ltd. | 4430 | 2015-03-05 | 2024-10-31 | |
| Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile? Environmental sampling, Skin swab sampling, Fecal sampling - Clostridium Difficile Infection | Completed | Professor Mark Wilcox | 203 | 2015-01-01 | 2021-09-09 | |
| A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone Enzalutamide, Docetaxel, Prednisolone - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Completed | Astellas Pharma Europe Ltd. | 688 | 2014-12-01 | 2025-04-08 |
| A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice Betmiga® - Urgency Incontinence, Urinary Bladder Overactive | Completed | Astellas Pharma Europe Ltd. | 863 | 2014-11-25 | 2024-10-31 | |
| A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population Fidaxomicin, Vancomycin - Clostridium Difficile | Phase 4 | Completed | Astellas Pharma Europe Ltd. | 364 | 2014-11-06 | 2024-10-31 |
| A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease Eligard - Metastatic Prostate Cancer | Phase 4 | Terminated | Astellas Pharma Europe Ltd. | 1 | 2014-08-01 | 2017-03-09 |
Showing 20 of 38. Sign in to see all of them.
Prostatic Neoplasms (6) · Urinary Bladder, Overactive (5) · Urinary Bladder Diseases (3) · Urologic Diseases (3) · Clostridium Infections (2) · Hot Flashes (2) · Neoplasm Metastasis (2) · Renal Insufficiency, Chronic (2) · Urinary Incontinence (2) · Adenocarcinoma (1) · COVID-19 (1) · Coronavirus Infections (1) · Herpes Genitalis (1) · Herpes Zoster (1) · Infections (1)
Tacrolimus (9) · enzalutamide (5) · Fidaxomicin (3) · Solifenacin Succinate (3) · mirabegron (3) · Capsaicin (2) · OPT 80 (2) · Prednisolone (2) · Vancomycin (2) · fezolinetant (2) · ASP2151 (1) · Docetaxel (1) · Hydrocortisone (1) · Leuprolide (1) · Mycophenolic Acid (1)
United Kingdom (23) · France (19) · Poland (15) · Spain (15) · Belgium (14) · Germany (14) · Italy (14) · Austria (12) · Czechia (12) · Sweden (12) · Greece (11) · Canada (9) · Ireland (9) · Netherlands (9) · Denmark (8)
Andreas Josefsson, MdPhD (1) · Bertrand Tombal, Prof (1) · Mark H Wilcox (1)
PMID 26965560, PMID 27773449, PMID 28431564, PMID 28624338, PMID 28916436, PMID 29134426, PMID 29205855, PMID 29231747, PMID 29254376, PMID 29273269, PMID 29754400, PMID 30260412, PMID 30591285, PMID 30665258, PMID 30911926, PMID 32126998, PMID 33726804, PMID 34554688, PMID 35331039, PMID 36265504, PMID 37847872, PMID 38529215, PMID 39827019, PMID 41313045
2009 (3), 2005 (2), 2014 (2), 2017 (1)